Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Amytal Sodium
Synonyms :
amobarbital
Class :
Barbiturate
Brand Name :
Amytal Sodium
Synonyms :
amobarbital
Class :
Barbiturate
Dosage Forms & Strengths Â
Powder for injection Â
500mg Â
Sedative Â
30-50 mg IV 2-3 times a day Â
Hypnotic Â
At bedtime, 65-200 mg IV Â
30-50 mg IV 2-3 times a day 
At bedtime, 65-200 mg IV 
Dosage Forms & Strengths Â
Powder for injection Â
500mg Â
Sedative Â
Age: 6-12 years Â
65-500 mg IV/IM Â
Age: > 12 years Â
30-50 mg IV 2-3 times a day Â
Hypnotic Â
Age: 6-12 years Â
2-3 mg/kg IV/IM Â
Age: > 12 years Â
At bedtime, 65-200 mg IV Â
Age: 6-12 years 
65-500 mg IV/IM 
Age: > 12 years 
30-50 mg IV 2-3 times a day 
Age: 6-12 years 
2-3 mg/kg IV/IM 
Age: > 12 years 
At bedtime, 65-200 mg IV 
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
amobarbital: it may decreased the serum concentration of CNS depressants
amobarbital: it may decreased the serum concentration of CNS depressants
amobarbital: it may decreased the serum concentration of CNS depressants
amobarbital: it may decreased the serum concentration of CNS depressants
amobarbital: it may decreased the serum concentration of CNS depressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may increase the action of CNS depressants inducing CNS depression
bunazosin (Not available in the United States)
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may enhance the risk of adverse effect of dapsone
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may enhance the toxic effect of each other when combined
may have an increased effect of CNS depression when combined with Amobarbital
may increase the risk of adverse effects when combined with each other
may enhance the area under the curve when co-administered
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
amobarbital decreases the effect of fedratinib by altering the intestinal/hepatic CYP3A4 enzyme metabolism
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
may reduce the therapeutic effect of hemin
methyldopa/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
It may enhance sedation when combined with tramadol
It may enhance sedation when combined with a shepherd's purse
It may enhance sedation when combined with codeine
may have an increased hypotensive effect when combined with antihypertensive agents
it may diminish the therapeutic efficacy when combined with castor oil
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
It may enhance sedation when combined with oxycodone
it may enhance the sedation when combined with lofexidine
It may diminish the levels when combined with tamsulosin by affecting CYP3A4 metabolism
When metixene and amobarbital are combined, the risk or seriousness of adverse events will rise
When used with amobarbital, levobetaxolol's serum levels may reduced
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
The potential for increased CNS depression risk or seriousness occurs when amobarbital is used together with pinazepam
When amobarbital is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with amobarbital, There is a risk or seriousness of CNS depression is enhanced
When amobarbital is used together with medazepam, the risk or seriousness of CNS depression is enhanced
When amobarbital is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When amobarbital is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When chlordiazepoxide is used together with amobarbital, this leads to enhanced risk or seriousness of CNS depression
When amobarbital is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
When amobarbital is used together with norelgestromin, this leads to a rise in norelgestromin’s metabolism
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
When amobarbital is used together with isoflurophate, this leads to a reduction in the therapeutic effectiveness of amobarbital
When emylcamate is used together with amobarbital, this leads to enhanced risk or seriousness of CNS depression
When amobarbital is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with amobarbital, this leads to enhanced risk or seriousness of CNS depression
when used in combination with ambenonium, the therapeutic effectiveness of amobarbital may be diminished
amobarbital: it may decreased the serum concentration of oxtriphylline
the intensity of adverse effects can be elevated when amobarbital is combined with dapoxetine
When amobarbital is used together with profenamine, this leads to enhanced risk or seriousness of adverse events
hepatic enzyme metabolism i.e., CYP3A4 metabolism is affected when amobarbital used combinely with lidocaine and lowering its levels
when both drugs combine amobarbital will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs are combined, there may be an increased metabolism of paclitaxel 
when both drugs are combined, there may be a decreased level of serum concentration of erlotinib  
they increase the effect of hypotension on other hypotensive agents
they increase the effect of hypotension on other hypotensive agents
they increase the metabolism of norepinephrine reuptake inhibitors
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may increase the serum concentration of Cardiac Glycosides
may increase the serum concentration of Cardiac Glycosides
may increase the serum concentration of Cardiac Glycosides
may increase the serum concentration of Cardiac Glycosides
may increase the serum concentration of Cardiac Glycosides
valproate increases the concentration of serum barbiturates in the serum
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may increase the serum concentration of cardiac glycosides
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
relugolix/​estradiol/​norethindroneÂ
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
may enhance the risk of adverse/toxic effect of artemether/lumefantrine
may increase the hypotensive effect of antihypertensives
may increase the hypotensive effect
may increase the hypotensive effect of anti-hypertensives
may increase the hypotensive effect of blood pressure-lowering agents
hydrochlorothiazide/aliskirenÂ
may increase the hypotensive effect of blood pressure-lowering agents
may increase the hypotensive effect of blood pressure-lowering agents
lisinopril/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
eprosartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
valsartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may increase the hypotensive effect of blood pressure-lowering agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
may decrease the hypotensive effect of Blood Pressure Lowering Agents
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
may increase the hypotensive effect of barbiturates
the therapeutic activity of amobarbital may be reduced
an increase in CNS depression may be seen
combining zimelidine with amobarbital may increase the chances of adverse effects
the hypotensive activity of candesartan cilexetil may be increased
the risk of CNS depression may be increased
When amobarbital is used together with lomitapide, this leads to an enhancement in lomitapide’s metabolism
cinnarizine and dimenhydrinateÂ
this combination will make you feel sleepy or tired when Tranquillisers used in combination
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
when both drugs are combined, there may be an increased metabolism of alpelisib    
it decreases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it decreases the effect or level of dutasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
Adverse drug reactions Â
Frequency DefinedÂ
1-10% Â
Somnolence Â
<1% Â
psychiatric disturbance Â
Hallucinations Â
Agitation Â
Nightmares Â
Hypotension Â
Syncope Â
Confusion Â
Hyperkinesia Â
Ataxia Â
CNS depression Â
Nervousness Â
Bradycardia Â
Pregnancy warnings:   
Pregnancy Category: DÂ
Lactation: Â
Excreted into human milk is known Â
Pregnancy Categories:       Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were no enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Patient Information Leaflet   Â
Generic Name: amobarbitalÂ
Why do we use amobarbital? Â
amobarbital is a Barbiturate. It is used to relax before surgical procedure and treat sleep problems.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
